GlassScriptPhysician profile
Hong Cai
NPI 1851056303
$2,170.02
in general payments reported to CMS, 2019-2025
31 companies · $772 in 2025
The $772 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.52 · 2023: $680 · 2024: $705 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.55 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $422.19 | 2023-2025 | Libtayo |
| Janssen Biotech, INC. | $265.72 | 2023-2025 | Darzalex, Rybrevant, Tecvayli |
| Merck Sharp & Dohme LLC | $150.06 | 2023-2025 | Keytruda, Welireg, Reblozyl |
| Taiho Oncology, INC. | $142.52 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.24 | 2023-2025 | Imfinzi, Calquence, Lynparza |
| Pharmacyclics LLC, An Abbvie Company | $108.27 | 2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $96.70 | 2024-2025 | Fruzaqla, Alunbrig |
| Abbvie INC. | $76.74 | 2023-2025 | |
| Incyte Corporation | $73.46 | 2022-2025 | Jakafi, Monjuvi |
| Tersera Therapeutics LLC | $67.37 | 2024-2025 | Zoladex |
| Lilly USA, LLC | $59.93 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $53.05 | 2025 | Jemperli, Ojjaara |
| Iovance Biotherapeutics, INC. | $46.71 | 2025 | Amtagvi |
| Genmab U.S., INC. | $45.95 | 2023-2024 | Epkinly |
| Genzyme Corporation | $45.69 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $41.55 | 2023-2025 | Opdualag |
| Rigel Pharmaceuticals, INC. | $40.37 | 2023-2025 | Rezlidhia, Gavreto, Tavalisse |
| Pfizer INC. | $35.90 | 2024-2025 | |
| Celgene Corporation | $30.66 | 2023-2024 | Reblozyl |
| Seagen INC. | $27.40 | 2023 | Padcev |
| Ipsen Biopharmaceuticals, INC | $26.39 | 2024 | Onivyde |
| Astellas Pharma US INC | $24.41 | 2023 | Padcev |
| Aadi Bioscience, INC. | $23.91 | 2023 | Fyarro |
| Beigene USA, INC. | $21.34 | 2024 | Tevimbra |
| Syndax Pharmaceuticals, INC. | $21.19 | 2025 | |
| Beone Medicines USA, INC. | $20.25 | 2025 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $19.53 | 2025 | Qinlock, Romvimza |
| Recordati_rare_diseases_inc. | $19.06 | 2023 | Sylvant |
| Genentech USA, INC. | $16.97 | 2025 | Tecentriq Hybreza |
| Array Biopharma INC | $16.00 | 2023 | Xalkori, Lorbrena, Braftovi |
| Pharmaessentia USA Corporation | $13.49 | 2025 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong Cai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.